Natera launched its Prospera donor-derived cfDNA (dd-cfDNA) transplant assessment test for lung transplant recipients.Natera said it validated the Prospera Lung test in the...
Natera (NTRA) highlights the publication of a new study of its personalized and tumor-informed molecular residual disease ((MRD)) test, Signatera, to assess tumor growth rates...
Natera completed the VALID study for Prospera test in lung transplant recipients.VALID (Validation for Allograft Lungs Implementing Donor-derived cell-free DNA) study will...
Mesa Labs MLAB is a $1.6 billion provider of quality control monitoring and validation instruments serving niche markets in healthcare, industrial, pharmaceutical, medical and food...
Double-digit dividends are rare. A sky-high yield of 27.2% is an outright income unicorn.Only in the merry world of closed-end funds (CEFs) would we see such a tale. It’s...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Sell | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Neutral | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 313.85 | 330.17 | 312.93 | -14.84 | -4.51% | 38.06M | NASDAQ | |||
| 149.59 | 150.84 | 149.02 | +0.95 | +0.64% | 32.82M | NASDAQ | |||
| 2,780.00 | 2,800.30 | 2,767.90 | +31.1 | +1.13% | 1.08M | NASDAQ | |||
| 61.97 | 63.08 | 61.62 | -0.14 | -0.23% | 7.55M | NYSE | |||
| 248.12 | 252.59 | 239.25 | +16.46 | +7.11% | 31.07M | NASDAQ | |||
| 47.98 | 49.44 | 47.99 | -1.42 | -2.88% | 35.42M | NASDAQ | |||
| 169.42 | 174.86 | 168.88 | -6.75 | -3.83% | 10.40M | NYSE | |||
| 330.48 | 351.00 | 330.30 | -45.85 | -12.18% | 5.50M | NYSE | |||
| 25.95 | 26.74 | 25.39 | +0.54 | +2.13% | 35.41M | NYSE | |||
| 242.11 | 249.88 | 241.18 | -4.77 | -1.93% | 7.94M | NASDAQ | |||
| 28.20 | 28.63 | 28.15 | -0.02 | -0.07% | 3.83M | NASDAQ | |||
| 263.52 | 270.16 | 262.69 | +1.52 | +0.58% | 4.10M | NYSE | |||
| 36.13 | 37.03 | 36.03 | -0.70 | -1.90% | 12.48M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 345.80 | 356.69 | 342.53 | -3.76 | -1.08% | 4.57M | NASDAQ |
Natera, Inc. is a diagnostics company. The Company is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. The Company’s cell-free DNA (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening (HCS), Spectrum Pre-implantation Genetics (Spectrum), Anora Miscarriage Test (Anora), Non-Invasive Paternity Testing (PAT) and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology.